Preventive strategies for group B streptococcal and other bacterial infections in early infancy: Cost effectiveness and value of information analyses

Medicine and Dentistry

• Health Care Cost 100%
• Infancy 100%
• Cost-Effectiveness Analysis 100%
• Bacterial Infection 100%
• Obstetric Delivery 50%
• Polymerase Chain Reaction 50%
• Infection 25%
• Vaccine 25%
• Penicillin Derivative 25%
• Systematic Review 25%
• Antibiotic Therapy 25%
• High Risk Population 25%
• Quality Adjusted Life Year 25%
• Erythromycin 25%
• Streptococcus Agalactiae 25%
• Group B Streptococcal Infection 25%
• Newborn Infection 25%

Nursing and Health Professions

• Cost Effectiveness Analysis 100%
• Bacterial Infection 100%
• Obstetric Delivery 66%
• Polymerase Chain Reaction 66%
• Systematic Review 33%
• Health Care Cost 33%
• Quality Adjusted Life Year 33%
• Infection 33%
• Vaccine Efficacy 33%
• High Risk Population 33%
• Newborn Infection 33%
• Antibiotic Therapy 33%
• Penicillin Derivative 33%
• Erythromycin 33%
• Group B Streptococcal Infection 33%
• Vaccine 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Bacterial Infection 100%
• Infection 50%
• Penicillin Derivative 50%
• Erythromycin 50%
• Vaccine 50%
• Streptococcus Agalactiae 50%
• Newborn Infection 50%
• Group B Streptococcal Infection 50%